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RADIOLOGY & IMAGING | RESEARCH ARTICLE
Assessment of uterine fibroid infarction after 
embolization with tris-acryl gelatin microspheres
S. Duvnjak1,2*, P. Ravn3, A. Green2 and P.E. Andersen1
Abstract: Purpose: To evaluate the degree of fibroid infarction after uterine fibroid 
embolization (UFE) with tris-acryl gelatin microsphere (Embosphere) visualized by 
contrast-enhanced magnetic resonance imaging (MRI) and evaluation of the clinical 
outcome measured with symptom and quality of life questionnaire (UFS-QOL) after 
3 months follow-up. Materials and Methods: A prospective study included twenty-
six pre-menopausal women. UFE with Embosphere of 500–900 μm was performed. 
Residual contrast enhancement in the total fibroid burden was analyzed and residu-
al contrast enhancement ≤10% was defined as a satisfactory result after emboliza-
tion. The dominant fibroids and total uterine volumes were assessed by MRI before 
and at follow-up. The UFS-QOL questionnaire answers were analysed and compared. 
Results: Twenty-five of 26 patients (96%) had a technically successful UFE. Twenty-
four of the patients (92%) had MRI controls 3 months after UFE of which 23 patients 
had complete or almost complete fibroid burden infarction without residual contrast 
enhancement of the fibroids of more than 10%. One patient had insufficient fibroid 
burden infarction. Twenty-three of the patients had UFS-QOL analyses of which 96% 
had significant clinical improvement. Conclusion: UFE with Embosphere of 500–
900 μm gave satisfactory MRI results with residual fibroid contrast enhancement 
≤10% and good clinical effect in 96% of patients.
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The uterine fibroid is very frequent female 
benign tumour with impact on quality of life in 
a symptomatic patients. The mains symptoms 
are bleedings, pressure symptoms and pain. 
I some cases the fibroid cause infertility. The 
surgical treatment was the standard treatment, 
but after the well-conducted randomised study, 
the majority of the Europea and North American 
Gynaecological society include minimally invasive 
treatment such as uterine artery embolization 
(UAE) as a treatment option. With UAE the 
quality of life and symptoms control are achieved 
in a majority of the patients. However, the 
reintervention rate is more frequent compared 
with the surgical hysterectomy. Compared with 
the another uterus sparing surgical modality re-
intervention is similar.
The unanswered question is safety of UAE 
in a patients who want to be pregnant. There 
is no strong evidence to support either the 
myomectomy or UAE in this group of patients and 
more evidence is needed.
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1. Introduction
Uterine fibroid embolization (UFE) is a well-established treatment of symptomatic fibroids with clini-
cal efficacy comparable with traditional surgical treatment (Gupta, Sinha, Lumsden, & Hickey, 2014). 
Since introduction there has been a lot of investigations of fibroid characteristics, imaging of the fi-
broids, technical details during interventions and investigation of the available embolic agents re-
garding clinical and imaging outcome (Katsumori, Kasahara, Kin, & Nozaki, 2008; Spies, 2013). The 
first generation of microparticles is non-spherical polyvinyl alcohol particles (ns-PVA, Boston 
Scientific, Natick, MA, USA and Ivalon, Cook Medical, Bloomington, IN, USA) which showed favoura-
ble results but the non-spherical shape had some disadvantages and following the calibrated 
spheres has been developed. Currently, there are five types of microspheres available, tris-acryl 
gelatin microsphere (Embosphere, Merit Medical, Paris, France), Acrylamido polyvinyl alcohol micro-
sphere (Bead Block, Biocompatibles, Farnham UK), polymer Polyzene-F (Embozene, CeloNova, 
Bioscience San Antonio, Texas, USA), Polyethylene glycol microsphere (HydroPearl, Terumo Europe, 
Leuven, Belgium) and spherical polyvinyl alcohol microsphere (Contour SE, Boston Scientific, Natick, 
MA, USA). The clinical and imaging outcomes after use of spherical polyvinyl alcohol microspheres 
(s-PVA) and Embosphere have been studied extensively showing that Embospheres achieved better 
results (Rasuli et al., 2008; Siskin et al., 2008; Spies et al., 2005). The potential difference between 
Embosphere and Bead Block has not been studied extensively, and there is still no evidence in favour 
of any of these microspheres (Das, Champaneria, Daniels, & Belli, 2014).
In the upstart of UFE in 1999 at our institution we used ns-PVA and switched after introduction of 
spherical microspheres on the market to s-PVA, but the results and achievement with this type of 
embolic agent were not optimal (Duvnjak, Ravn, Green, & Andersen, 2016). During the latest few 
years, we have used Bead Block as an embolic agent for UFE but demonstrated insufficient fibroid 
infarction in 27% of the patients (Duvnjak, Ravn, Green, & Andersen, 2017). Therefore a prospective 
study was initiated to investigate completeness of fibroid infarction and residual contrast enhance-
ment of the total fibroid burden after UFE using the Embosphere of 500–900 μm in size as embolic 
agent.
The working hypothesis was that Embosphere might be a more potent embolic agent than the 
others and can give more complete embolization in a majority of the patients.
Primary aim of the study was to evaluate the rate of fibroid infarction and the residual total fibroid 
burden after UFE with Embosphere demonstrated by contrast-enhanced magnetic resonance imag-
ing (MRI). Secondary aim was to investigate the clinical outcome after three months follow-up using 
a validated uterine fibroid symptom and quality of life (UFS-QOL) questionnaire (Spies et al., 2002).
2. Material and methods
Informed consent was waived for all participants, and the regional ethic committee approved the 
study (S-20120138). Twenty-six patients with symptomatic fibroids entered the study from February 
2015 to May 2016. The baseline non-contrast- and contrast enhanced MRI before UFE were performed 
in all cases. The follow-up protocol included three months post UFE MRI control. All patients were 
asked to answer the UFS-QOL questionnaire at baseline and at follow-up three months after UFE.
2.1. Study design
All consecutive symptomatic patients with menorrhagia, metrorrhagia, bulk-related symptoms or a 
combination of these symptoms who accepted to participate were included in the study. The gynae-
cologist examined all patients and confirmed the diagnosis of symptomatic fibroids and excluded 
other diseases. The residual contrast enhancement of the fibroids and the uterine and dominant fi-
broid volumes was analysed by MRI and compared with baseline data at three months MRI control. 
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The official Danish translation of the UFS-QOL questionnaire was provided by the authors and per-
mission to use the translated questionnaire subsequently granted by the Society of Interventional 
Radiology. Exclusion criteria were: asymptomatic fibroids, active pelvic infection, malignancy, preg-
nancy, age <18 years and >52 years, non-contrast enhancing of the fibroids at the baseline exami-
nation and adenomyosis.
2.2. Intervention
All procedures were performed under local anaesthesia. UFE was performed by the same IR special-
ist, in all but one case using transfemoral percutaneous access and in one case by left trans-brachial 
access due to obesity. The patients had a self-controlled morphine analgesia pump. Peroral pain 
drugs and antiemetic drugs were prescribed when needed. After selective bilateral catheterization 
of the internal iliac arteries, “microcatheter” (Direxion HI-FLO, inner lumen 0,027″ Boston Scientific, 
Natick,MA,USA) “microcatheter” were placed in a transversal part of the uterine artery. The emboli-
zation with Embosphere microspheres was performed until “near” flow-stop defined as sluggish 
flow through the horizontal part of the main uterine artery and flow stop in the peri fibroid arteries 
on the both sides. The patients were embolized with 500–700 μm microspheres and if the desired 
end-point was not achieved after 6 ml of these microspheres embolization were followed by 700–
900 μm microspheres till near flow stop. The achievement of the end-point was confirmed after five 
minutes waiting by flushing contrast in all cases. In case of incomplete flow-stop, supplementary 
embolization was performed. Finally, abdominal aortography was performed to disclose possible fi-
broid supply from the ovarian arteries. At the discretion of the patients, it was decided whether or 
not to perform supplementary embolization of the ovarian artery.
2.3. MRI analyses
MRI using phased array torso coil was performed with 1.5 Tesla MR Systems, (Philips Medical System, 
the Netherlands). The standard MR fibroid protocol consists of non-contrast T1, and T2 weighted 
axial and sagittal as well as fat saturated post contrast T1 trans-axial gradient recalled echo and 
turbo spin echo image sequences (Kirby, Burrows, Haider, Maizlin, & Midia, 2011). The largest domi-
nant fibroid volume and total uterine volume using the ellipsoid formula (length × height × width × 0, 
52), the number of fibroids and dominant fibroid localisation were analysed and recorded. The fi-
broid burden infarction after UFE and residual fibroid burden contrast enhancement were visually 
estimated by contrast-enhanced MRI at follow-up after three months. Results were stratified into 
three categories: category 1: 100% fibroid infarction = no residual enhancement (Figure 1(A)–(B)), 
category 2: 99–90% fibroid infarction with residual fibroid contrast enhancement less than 10% 
(Figure 2(A)–(B)), and category 3: less than 90% fibroid infarction with residual contrast fibroid en-
hancement more than 10% (Figure 3(A)–(B)). The first two categories were defined as successful 
outcomes and category three as an unsuccessful outcome. Dominant fibroid infarction, as well as 
Figure 1. (A) Presents contrast-
enhanced MRI of the fibroid 
prior to UFE. (B) Presents the 
same fibroid after UFE with 
complete fibroid infarction 
(100%) without residual 
contrast enhancement. 
Category 1.
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complete fibroid burden infarction, were analysed as described above. The fibroid and uterine vol-
ume changes were reviewed accordingly at follow-up images and compared with baseline measure-
ment. Two radiologists, one with over 7-years’ experience in pelvic MRI imaging and the other with 
5 years experience reviewed the images in consensus in a non-blinded fashion.
2.4. UFS-QOL questionnaire analyse
The UFS-QOL questionnaire consists of an 8-item symptom severity scale and 29-item health-related 
quality of life (HRQOL) comprising six domains: Concern, activities, energy/mood, control, self-
consciousness, and sexual function. The Likert 5-point scale, ranging from “not at all” to “a very 
great deal” for symptom severity score and a range from “none of the time” to “all of the time” for 
the HRQOL score was used for questionnaire analysis. Both scores were summed and transformed 
into a 0–100 point scale (Spies et al., 2002). High symptom severity score indicates severe symptoms 
and a high HRQOL score indicates a good quality of life.
2.5. Statistical analyze
Continuous variables are expressed as mean (±standard deviation-SD) or median, as appropriate. 
Nominal data are given as absolute numbers and percentages. Numerical variables were compared 
using two-tailed Student’s t-test. Wilcoxon paired sample test was used to compare results of the 
Figure 2. (A) Presents contrast-
enhanced MRI of the fibroid 
prior to UFE. (B) Presents 
the same fibroid after UFE 
with almost complete fibroid 
infarction (90–99%) and 
residual contrast enhancement 
below 10%. Note small 
irregularity on the base of 
embolized fibroid. Category 2.
Figure 3. (A) Presents contrast-
enhanced MRI of the fibroid 
prior to UFE. (B) present the 
same fibroid after UFE with 
incomplete fibroid infarction 
(<90%) and with residual 
contrast enhancement over 
10%. The central part of the 
fibroid is with residual contrast 
enhancement. Category 3.
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UFS-QOL questionnaire score using the SSPS software package (Statistics 21 IBM Corporation NY, 
USA). Statistical significance was set at p < 0. 05.
3. Results
In the period February 2015 until May 2016, 31 patients were referred for UFE. Twenty-six patients 
were included in the study while four patients desisted to participate and one patient was excluded 
because of high age.
3.1. Baseline characteristics
The mean age in the entire group was 44.5 year (range: 32–52). The patients’ dominant symptoms 
and MRI fibroid characteristics are presented in Table 1.
3.2. UFE intervention
Twenty-five patients (96%) had a technically successful UFE performed with complete flow-stop in 
both uterine arteries and no associated peri-procedural complications. The end-point of near com-
plete stasis of flow was achieved in all cases. In one patient (4%) the left uterine artery was too small 
and hypoplastic to allow safe particle administration without the risk of reflux and following non-
target embolization. There was one case with additional left ovarian artery fibroid vascular supply 
left untreated due to the patient’s wish. There were no cases which required additional embolization 
after five minutes waiting. Prophylactic antibiotics were not administrated in any case according to 
our treatment protocol. The average volume of microspheres used per patient was 9.1 ml (range: 
6–16 ml).
3.3. MRI follow-up
Twenty-four patients (92%) completed three months follow-up with MRI. One patient did not 
complete three months control and withdrew from the study and another patient underwent 
hysterectomy two months after UFE. Twenty-three of the 24 patients, (96%) had complete fibroid 
burden infarction and/or residual contrast enhancement of the fibroid burden of less than 10% at 
three months MRI control (category 1 and/or 2). One of the 24 patients, (4%) had insufficient 
dominant fibroid infarction with residual contrast enhancement of more than 10% (category 3). The 
left ovarian artery was left patent in this patient which might be responsible for the residual contrast 
enhancement. The other patient with a hypoplastic left uterine artery which was not embolized had 
on follow-up MRI no residual enhancement in the fibroids (Figure 4(A)–(C)). The median dominant 
fibroid volume reduction was presented with a statistically significant reduction of 49% after three 
months follow-up (p < 0.01). The median uterine volume reduction was 47% which was a significant 
reduction compared with baseline (p < 0.007).
Table 1. Patients symptoms and MRI characteristics
Dominant symptom and MR characteristics Number of patients/percentage
Patients symptoms •  Predominantly bleeding—11 (42%)
•  Predominantly bulk-related symptoms—5 (19%)
•  Both (bleeding and bulk-related)—10 (39%)
Dominant fibroid localization •  Intramural—23 (88%)
•  Subserosal—2 (8%)
•  Submucosal—1 (4%)
Number of fibroids •  1 fibroid—10 (38%)
•  2–5 fibroids—13 (50%)
•  >5 fibroids—3 (12%)
Uterus volume prior to UFE—cm³ Median/range
500.3 cm³/ (93.7–1,149.2 cm³)
Dominant fibroid volume prior to UFE—cm³ Median/range
186.3 cm³ (26.4–484.1 cm³)
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3.4. UFS-QOL questionnaire analysis-clinical outcome
Twenty-three patients completed the UFS-QOL questionnaires including baseline and three months 
follow-up. The median HRQOL score prior to UFE was 62 (range: 6–94) and had improved significantly 
after three months to 81 (p < 0.001). The median symptom severity score prior to UFE was 65 (range: 
25–93) and had been significantly decreased after three months to 33 (p < 0.001). In Figure 5 the 
median HRQL score and symptom severity score changes are graphically presented. Only one pa-
tient (4%) had an increased symptom severity score. Two patients (9%) had unchanged HRQOL 
score, but these patients at the same time had significant decreasing of symptom severity score.
Complications were classified according to the SIR classification (Hovsepian et al., 2009). One 
patient (5%) underwent hysterectomy two months after UFE due to symptom persistence and 
hospital admission >48 h, classified as SIR complication D. Two patients (9%) had non-bacterial 
endometritis treated with antibiotics without further problems. They required admission < 48 h and 
have been classified as SIR complication C due to pain and prolonged discharge, one patient had an 
extended hospital admission but <48 h, which was classified as SIR complication C also. Three 
patients experienced clinical “silent” fibroid expulsion requiring no further treatment.
4. Discussion
UFE has an established role in the treatment of symptomatic fibroids (Hehenkamp, Volkers, Birnie, 
Reekers, & Ankum, 2008; Manyonda et al., 2012; The REST Investigators, 2007). During the last two 
decades, technical and imaging improvements have contributed to the mastering of the interven-
tion. There are not many unknown remaining issues during UFE, especially from the technical point 
of view. After Spies in 2005 (Spies, 2009) questioned what type of evidence we need before adopting 
a new embolic agent, the level of evidence has been increasing (Golzarian et al., 2006; Spies, Cornell, 
Worthington-Kirsch, Lipman, & Benenati, 2007). Further, MRI control is essential to ensure quality 
after UFE and is the most commonly used modality for follow-up (Katsumori et al., 2008; Kroencke, 
Scheurig, Poellinger, Gronewold, & Hamm, 2010). The still not so clear issue is a behaviour of the dif-
ferent embolic agents and availability to obtain complete fibroid infarction, or precise some of 
them. Das et al. (2014) in a meta-analysis emphasised that still, we do not have strong evidence 
comparing Embosphere with Bead Block microspheres. The new embolic agent like Embozene and 
HydroPearl are not included in the meta-analysis as well.
The fibroid infarction degree has a strong correlation with especially long-term clinical successful 
outcome where patients with fibroid infarction ≥90% have better clinical results comparing with 
patients with fibroid infarction below 90% (Katsumori et al., 2008; Koesters, Powerski, Froeling, 
Kroencke, & Scheurig-Muenkler, 2012; Worthington-Kirsch, Siskin, & Hegener, 2009). Katsumori et al. 
(2008) showed at five year follow up that cumulative rate of symptom control was 93% for patients 
Figure 4. (A) Presents fibroid 
prior to UFE. The left uterine 
artery was not embolized due 
to small calibre. (B) Presents 
almost complete fibroid 
vascularization from the right 
uterine artery. (C) Presents 
control contrast enhancing MRI 
with complete fibroid infarction 
despite the left uterine artery 
was not embolized.
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with complete fibroid infarction compared regarding symptom control in only 60% of the patients 
with fibroid infarction below 90%. Further, Koesters et al. (2012) reported that among 22 patients 
with complete fibroid infarction, 20 patients had no symptom recurrence after eight years follow-up, 
in contrast with six patients with fibroid infarction below 90% who all had symptom recurrence. 
Gabriel-Cox, Jacobson, Armstrong, Hung, and Learman (2007) concluded that incomplete fibroid 
infarction is the most likely cause of recurrence of symptoms. They compared patients with unin-
tended unilateral UFE who had a re-intervention rate of 39.2% with patients with bilateral UFE which 
had a re-intervention rate 18.5%. In conclusion, the majority of the authors suggest that fibroid in-
farction should be ≥90%, but some authors suggest ≥80% of fibroid infarction as sufficient result 
(Smeets et al., 2010).
The present study showed that 96% of the patients obtained complete or almost complete fibroid 
infarction after UFE with the use of Embosphere 500–900 μm in size. Only one patient had insuffi-
cient MRI result with a residual fibroid burden contrast enhancement above 10%, probably due to 
additional fibroid vascular supply from the ovarian artery. In a recently published study showed in-
ferior performance of Bead Block particles compared with Embosphere particles which were used in 
the present study (Duvnjak et al., 2017). The patients’ demography, symptoms, and embolization 
technique and endpoints were comparable in the two studies which allow us to draw this conclusion. 
Spies et al. (2005) achieved similar high infarction rate in their study using Embosphere and reported 
Figure 5. The median changes 
in the HRQOL and symptoms 
severity score. (A) Significant 
increasing in HRQOL after UFE 
(p < 0.001). (B) Significant 
decreasing of symptoms 
severity score (p < 0.001).
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residual contrast enhancement in 5% of the patients. The same study showed residual contrast 
enhancement in 44.7% of the patients embolized with s-PVA.
The complications rate in the present study, especially fibroid expulsion, was a little higher com-
pared with other studies (Golzarian et al., 2006; Hehenkamp et al., 2008; Manyonda et al., 2012; 
Worthington-Kirsch et al., 2009) and one of the explanations could be submucosal and partial sub-
mucosal fibroid localisation in two cases. Endometritis is the other complication and can be ex-
plained with extensive embolization and following ischemia of the surrounding myometrial tissue. 
However, absent of major complications and clinical improvement are in line with other published 
results (Andersen et al., 2001; Spies, 2013).
The main limitations of this study are short-term follow-up and a relatively small number of pa-
tients. The other limitations are non-blinded MRI review and not a randomised comparison with the 
other embolic agents.
In conclusion, Embosphere (500–900 μm) achieved in 96% of the patients complete or almost 
complete fibroid burden infarction and present the best results until now in our praxis. Embosphere 
seems to be the most powerful microspheres for use in UFE today. The newer embolic agents should 
be examined in a prospective randomised study comparing with Embosphere before wider clinical 
use.
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